Claims for Patent: 9,087,145

Summary for Patent: 9,087,145

Title:	Ophthalmic drug delivery
Abstract:	The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.
Inventor(s):	Ballou, Jr.; Bernard L. (Raleigh, NC), Packer; Mark (Eugene, OR), Mumper; Russell John (Chapel Hill, NC), Inachulev; Tsontcho (San Mateo, CA)
Assignee:	Eyenovia, Inc. (Tampa, FL)
Application Number:	13/184,446
Patent Claims:	1. A method of delivering a medicament to an eye of a subject in need thereof as an ejected stream of droplets, the method comprising: (a) generating the ejected stream of droplets containing said medicament via a piezoelectric actuated ejection device, said ejector device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezo electric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation; wherein said ejected droplets have an average droplet ejecting size of between about 20 microns to about 100 microns in diameter and an average initial droplet ejecting velocity between 1 m/s and 10 m/s; and (b) delivering said ejected stream of droplets containing said medicament to said eye of the subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye. 2. The method according to claim 1, wherein said medicament is delivered in an aqueous droplet solution. 3. The method according to claim 2, wherein said medicament is delivered in an oil/water emulsion droplet. 4. The method according to claim 3, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture. 5. The method according to claim 1, wherein said medicament is a glaucoma medicament. 6. The method according to claim 1, wherein said medicament is an antibiotic. 7. The method according to claim 1, wherein said average droplet ejecting size is between about 30 microns to about 60 microns. 8. The method according to claim 1, wherein said average initial droplet ejecting velocity is between about 1 m/s to about 4 m/s. 9. The method according to claim 1, wherein said medicament is selected from the group consisting of ranibizumab antibody FAB, VEGF Trap fusion molecule, microplasmin enzyme, macugen pegylated polypeptide, and bevacizumab. 10. The method according to claim 1, wherein said medicament comprises a medicament selected from the group consisting of carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, pheniramine maleate, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bepotastine besilate, gatifloxacin, loteprednol etabonate, timolol ophthalmic, olopatadine hydrochloride, phenylephrine hydrochloride, levofloxacin, ketorolac tromethamine, latanoprost, bimatoprost and BAK free latanoprost. 11. The method according to claim 1, wherein said medicament comprises a medicament selected from the group consisting of fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, tetrahydrozoline HCl, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide HCl timolol maleate, azithromycin, brimonidine tartrate, nepafenac, brinzolamide, besifloxacin, dorzolamide HCl, prenisone acetate, loteprednol etabonate, tobramycin/dexamethasone, and cyclosporine. 12. The method according to claim 1, wherein said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost. 13. A method for providing a solution as an ejected stream of droplets to an eye of a subject in need thereof, the method comprising: (a) generating an ejected stream of droplets of said solution via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation; wherein said ejected droplets have an average droplet ejecting size of between about 20 microns to about 100 microns in diameter and an average initial droplet ejecting velocity of between about 1 m/s and 10 m/s; and (b) delivering said ejected stream of droplets of said solution to said eye of a subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye. 14. The method of claim 13, wherein said solution is an isotonic saline solution. 15. The method according to claim 13, wherein said solution comprises a medicament and said medicament is delivered in an aqueous droplet solution. 16. The method according to claim 13, wherein said solution comprises a medicament and said medicament is delivered in an oil/water emulsion droplet. 17. The method according to claim 16, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture. 18. The method according to claim 15, wherein said medicament is a glaucoma medicament. 19. The method according to claim 15, wherein said medicament is an antibiotic. 20. The method according to claim 13, wherein said average droplet ejecting size is between about 30 microns to about 60 microns. 21. The method according to claim 13, wherein said average droplet initial ejecting velocity is between about 1 m/s to about 4 m/s. 22. The method according to claim 15, said medicament is selected from the group consisting of ranibizumab antibody FAB, VEGF Trap fusion molecule, microplasmin enzyme, macugen pegylated polypeptide, and bevacizumab. 23. The method according to claim 15, wherein said medicament comprises a medicament selected from the group consisting of carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, pheniramine maleate, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bepotastine besilate, gatifloxacin, loteprednol etabonate, timolol ophthalmic, olopatadine hydrochloride, phenylephrine hydrochloride, levofloxacin, ketorolac tromethamine, latanoprost, bimatoprost and BAK free latanoprost. 24. The method according to claim 15, wherein said medicament comprises a medicament selected from the group consisting of fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, tetrahydrozoline HCl, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide HCl timolol maleate, azithromycin, brimonidine tartrate, nepafenac, brinzolamide, besifloxacin, dorzolamide HCl, prenisone acetate, loteprednol etabonate, tobramycin/dexamethasone, and cyclosporine. 25. The method according to claim 15, wherein said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost. 26. A method of treating glaucoma in a subject in need thereof comprising: (a) generating an ejecting stream of droplets containing a medicament for treatment of glaucoma via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation; wherein said droplets have an average droplet ejecting size of between about 20 microns to about 100 microns in diameter and an average initial droplet ejecting velocity of between about 1 m/s and 10 m/s; and (b) delivering said ejected stream of droplets containing said medicament to an eye of said subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye. 27. The method according to claim 26, wherein said medicament is delivered in an aqueous droplet solution. 28. The method according to claim 27, wherein said medicament is delivered in an oil/water emulsion droplet. 29. The method according to claim 28, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture. 30. The method according to claim 26, wherein said average droplets ejecting size is between about 30 microns to about 60 microns. 31. The method according to claim 26, wherein said average droplet initial ejecting velocity is between about 1 m/s to about 4 m/s. 32. The method according to claim 26, said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost. 33. A method of providing a reduced dosage of a medicament to an eye of a subject in need thereof as an ejected stream of droplets, the method comprising: (a) generating an ejected stream of droplets containing said medicament via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation; wherein said droplets have an average ejecting droplet size of between about 20 microns and about 100 microns in diameter and an average initial droplet ejecting velocity of between 1 m/s and 10 m/s; and (b) delivering said ejected stream of droplets containing said medicament to said eye of said subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye, and wherein said droplets provide a total volume of less than 30 .mu.l to said eye. 34. The method of claim 1, wherein said medicament has a viscosity at 25.degree. C. is about 0.3 centipoise (cP) to about 300 cP. 35. The method of claim 34, wherein said viscosity is about 0.3 cP to about 30 cP. 36. The method of claim 1, wherein said medicament is isotonic with human tears or eye tissue. 37. The method of claim 1, wherein said medicament has an osmolality ranging from about 100 milli-osmoles/kilogram (mmol/kg) to about 1000 mmol/kg. 38. The method of claim 37, wherein said medicament has an osmolality ranging from about 280 mmol/kg to about 320 mmol/kg.

Details for Patent 9,087,145

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2030-05-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2030-05-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2030-05-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2030-05-28